Navigation Menu

About Us

Harnessing the regenerative power of the human body to develop transformative medicines for CNS disorders

Photo of a lab worker

Our Mission

Our mission is to improve life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve.

CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease.  Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people.

Leadership Team

Anne M. Danks, Ph.D.Vice President, Preclinical Development Scott Forrest, Ph.D.Chief Business Officer Rohan Gandhi, Ph.D.Executive Director, Translational Neuroscience Jason Harris, Ph.D.Senior Director, Chemistry Deidre MacKenna, Ph.D.Vice President, Biology Christine MaurerSenior Vice President, Development Operations and Program Management John BorkholderGeneral Counsel and Senior Vice President, Administration Chan Beals, M.D., Ph.D.Senior Vice President, Translational Medicine Brian Stearns, Ph.D.Chief Scientific Officer Keith LendenCo-founder, President and Chief Operating Officer

Board of Directors

Diana Gallagher (Observer)Vice President, External Innovation, Biogen Timothy AndersonManaging Director, Cowen Healthcare Investments Richard Hargreaves, Ph.D., FBPhS (Observer)Senior Vice President, Head of Neuroscience TRC Research and Early Development, Bristol Myers Squibb Michael Baran, Ph.D., M.B.A. (Observer)Partner, Pfizer Ventures, Executive Director, External Science & Innovation, Worldwide R&D, Pfizer, Inc. Ben Cravatt, Ph.D.Professor and Gilula Chair of Chemical Biology, the Scripps Research Institute Kristina BurowManaging Director, ARCH Venture Partners Kevin FinneyChairman and CEO

Scientific Founders

Dennis Bourdette, M.D.Professor of Neurology, Oregon Health & Science University Ben Emery, Ph.D.Assistant Professor of Neurology, Oregon Health & Science University Tom Scanlan, Ph.D.Professor of Physiology and Pharmacology, Oregon Health & Science University

Scientific Advisors

Florian Eichler, M.D.Neurologist and Clinical Researcher, Harvard Medical School, Massachusetts General Hospital, Boston, MA Marc Engelen, M.D., Ph.D.Neurologist and Clinical Researcher, Amsterdam University Medical Centers Ben Cravatt, Ph.D.Professor and Gilula Chair of Chemical Biology, the Scripps Research Institute Tom Scanlan, Ph.D.Professor of Physiology and Pharmacology, Oregon Health & Science University

Investors

Logo for BVF Partners
Logo for Biogen
Logo for Bristo Meyers Squibb
Logo for Pfizer
Logo for Invus
Logo for Section 32
Logo for Samsara Biocapital
Logo for GT Healthcare
Logo for Alexandria Venture Investments

Our Science

Our Science